Results 241 to 250 of about 65,496 (283)

Blood Pressure‐Lowering Effect of SGLT2 Inhibitors in Patients Without Antihypertensive Treatment: A Real‐World Data Analysis

The Journal of Clinical Hypertension, Volume 28, Issue 2, February 2026.
ABSTRACT Sodium‐glucose co‐transporter 2 (SGLT2) inhibitors have demonstrated blood pressure (BP)‐lowering effects; however, most studies included patients taking antihypertensive medications. Using real‐world Japanese data, we assessed factors associated with SGLT2 inhibitor‐mediated BP reduction in patients not taking antihypertensive therapy.
Reina Ito, Michihiro Satoh, Hideaki Hashimoto, Hiroki Nobayashi, Seiya Izumi, Maya Toyama, Yutaro Iwabe, Yuya Suzuki, Takuo Hirose, Shingo Nakayama, Takahisa Murakami, Masato Sasaki, Hirohito Metoki   +12 more
wiley   +1 more source

Association between dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists and COVID-19 infection and adverse outcomes: a cohort study. [PDF]

BMJ Open Diabetes Res Care
Thompson W, Yu B, Porter J, Fang J, Ferreira-Legere LE, Austin PC, Jackevicius CA, Ross H, Lee DS, Weisman A, Farkouh ME, Gershon AS, Atzema CL, Kwong JC, Ha A, Džavík V, Udell JA.   +16 more
europepmc   +1 more source

A phase 1 single and multiple ascending dose study of orforglipron in Japanese participants with type 2 diabetes

Journal of Diabetes Investigation, Volume 17, Issue 2, Page 205-213, February 2026.
Orforglipron, a novel oral non‐peptide GLP‐1 receptor agonist, was evaluated in a Phase 1, double‐blind, placebo‐controlled, randomized, single and multiple ascending dose study in Japanese participants with type 2 diabetes. The safety and tolerability profile of orforglipron was consistent with those of other GLP‐1 receptor agonists, and ...
Kenji Ohwaki, Chino Nakamura, Risa Nasu, Kazumasa Takenouchi, Tetsuaki Hirase   +4 more
wiley   +1 more source

Psoriasis Risk Is Lower in Type 2 Diabetes Patients Using Dipeptidyl Peptidase-4 Inhibitors or Thiazolidinediones Compared to Sulfonylureas. [PDF]

Clin Transl Sci
Chen WS, Lin TM, Chang YS, Shen YC, Hsu HC, Kuo TT, Chen SC, Chen JH, Chang CC.   +8 more
europepmc   +1 more source

アログリプチンは非糖尿病被験者において食後高脂血症および食後血管内皮機能低下を改善する：予備報告 [PDF]

, 2015
Noda, Yoko
core  

Dipeptidyl peptidase-4 inhibitor approaches.

Journal of diabetes, 2019
openaire   +1 more source

Diabetic peripheral neuropathy as measured using a point‐of‐care sural nerve conduction device is associated with a faster decline in renal function in patients with type 2 diabetes

Journal of Diabetes Investigation, Volume 17, Issue 2, Page 291-300, February 2026.
Point‐of‐care assessment of diabetic peripheral neuropathy with DPN‐Check® was independently associated with a faster decline in renal function in type 2 diabetes, highlighting its potential as a tool to identify patients at high risk of kidney disease progression. ABSTRACT Aims/Introduction Diabetic peripheral neuropathy (DPN) is a common complication
Tatsuya Fukuda, Akiko Fujii, Taro Akihisa, Naoya Otsubo, Tetsuya Yamada, Chisato Maki   +5 more
wiley   +1 more source

Comparative risk of fibrosis progression with sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitors in metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus with low-to-intermediate fibrosis. [PDF]

Clin Mol Hepatol
Choi J, Fulop D, Nguyen VH, Przybyszewski E, Song J, Carroll A, Michta M, Almazan E, Simon TG, Chung RT.   +9 more
europepmc   +1 more source

The difference in type 2 diabetes care between the National Health Insurance beneficiaries and public assistance recipients in Japan: A retrospective cohort study based on claims data in a municipality

Journal of Diabetes Investigation, Volume 17, Issue 2, Page 347-359, February 2026.
We examined the differences in type 2 diabetes care between public assistance recipients and National Health Insurance beneficiaries in Japan by using claims data from a municipality. Public assistance might improve diabetes care process, but not fully health outcomes.
Takuya Yamaoka, Takehiro Sugiyama, Daisuke Nishioka, Naoki Kondo, Nanako Tamiya   +4 more
wiley   +1 more source

Anti-Inflammatory and Survival Benefits of Dipeptidyl Peptidase 4 Inhibitors Among Patients with Gout, T2DM Patients and Chronic Kidney Disease. [PDF]

Exp Clin Endocrinol Diabetes
Shiber S, Sharabi A, Ayalon I, Naamany E, Grossman A, Molad Y.   +5 more
europepmc   +1 more source